First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
This study is designed as an open-label, multi-center Phase 1 clinical study in participants with advanced malignant tumors to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of JMT108 injection, and to determine the RP2D/schedule for subsequent studies.
Advanced Malignant Tumors
DRUG: JMT108
Dose-Limiting Toxicity(DLT), To evaluate the safery of JMT108 in subjects., Approximately 28 days.|Adverse Events (AEs), To evaluate the safery of JMT108 in subjects, through study completion, an average of 1 year
Maximum plasma concentration (Cmax), To evaluate the systemic pharmacokinetics of JMT108 in subjects., through study completion, an average of 1 year
This study is designed as an open-label, multi-center Phase 1 clinical study in participants with advanced malignant tumors to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of JMT108 injection, and to determine the RP2D/schedule for subsequent studies.